search
Back to results

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease (SURMOUNT-J)

Primary Purpose

Obesity

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
Tirzepatide
Placebo
Sponsored by
Eli Lilly and Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Metabolism and Nutrition Disorder, Obesity Related Health Problems, Obesity Disease

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have a BMI of greater than or equal to ≥27 kg/m² and <less than 35 kg/m² with at least 2 obesity-related health problems or ≥35 kg/m² with at least 1 obesity-related health problems. Health problems are IGT, hyperlipidemia, or NAFLD.
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.

Exclusion Criteria:

  • Have diabetes.
  • Acute or chronic liver disease other than NAFLD.
  • Have a self-reported change in body weight >5 kg within 3 months prior to screening.
  • Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months.
  • Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2, calculated by Japanese Society of Nephrology coefficient-modified Chronic Kidney Disease-Epidemiology equation during screening.
  • Have a known clinically significant gastric emptying abnormality.
  • Have had a history of chronic or acute pancreatitis.
  • Have thyroid-stimulating hormone outside of the range of 0.4 to 6.0 micro units per milliliter (μIU/mL) at screening.
  • Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.
  • Have a history of significant active or unstable major depressive disorder or other severe psychiatric disorder within the last 2 years.
  • Have a cardiovascular condition within 3 months prior to randomization
  • Have a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome type 2.

Sites / Locations

  • Kohnodai Hospital, National Center for Global Health and Medicine
  • Saiseikai Matsuyama Hospital
  • Takai Internal Medicine Clinic
  • Motomachi Takatsuka Naika Clinic
  • Saiseikai Yokohamashi Tobu Hospital
  • Medical Corporation Heishinkai OCROM Clinic
  • Osaka Saiseikai Suita hospital
  • Takatsuki Red Cross Hospital
  • The Institute for Adult Disease, Asahi Life Foundation
  • Tokyo-Eki Center-building Clinic
  • Medical Corporation Chiseikai Tokyo Center Clinic
  • Fukuwa Clinic
  • Saiseikai Central Hospital
  • Shimokitazawa Tomo Clinic
  • Miho Clinic
  • Medical Corporation Heishinkai ToCROM Clinic
  • Yamagata Tokushukai Hospital
  • AMC Nishiumeda Clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Tirzepatide Regimen A

Tirzepatide Regimen B

Placebo

Arm Description

Tirzepatide Regimen A administered subcutaneously (SC)

Tirzepatide Regimen B administered subcutaneously (SC)

Placebo administered SC

Outcomes

Primary Outcome Measures

Percentage of Participants who Achieve ≥5% Body Weight Reduction
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Percent Change in Body Weight
Percent Change in Body Weight

Secondary Outcome Measures

Percentage of Participants Who Had Improvement in Obesity-related Health Problems
Percentage of participants who had improvement in at least 2 obesity-related health problems in participants with a baseline body mass index (BMI) ≥27 and <35 kilogram per square meter (kg/m²) or improvement in at least 1 obesity-related health problems in participants with a baseline BMI ≥35 kg/m²
Change from Baseline in Oral Glucose Tolerance (OGTT) 2-hr Glucose (Only for Participant with Impaired Glucose Tolerance [IGT] at Baseline)
Change from Baseline in OGTT 2-hr Glucose (Only for Participants with IGT at Baseline)
Change from Baseline in Fasting Glucose (Only for Participants with IGT at Baseline)
Change from Baseline in Fasting Glucose (Only for Participants with IGT at Baseline)
Change from Baseline in Fasting Lipids [Triglycerides (TG)] (Only for Participants with hyperlipidemia at Baseline)
Change from Baseline in Fasting Lipids TG (Only for Participants with hyperlipidemia at Baseline)
Change from Baseline in Hepatic Fat Fraction (HFF) (only for participants diagnosed as Non-alcoholic Fatty Liver Disease [NAFLD] by Magnetic Resonance Imaging (MRI) at Baseline)
Change from Baseline in HFF (only for participants diagnosed as NAFLD by MRI at Baseline)
Percentage of Participants Who Achieved Improvements of IGT (Only for Participants with IGT at Baseline)
Percentage of Participants Who Achieved Improvements of IGT (Only for Participants with IGT at Baseline)
Percentage of Participants Who Achieved Improvements of Hyperlipidemia (Only for Participants with Hyperlipidemia at Baseline)
Percentage of Participants Who Achieved Improvements of Hyperlipidemia (only for participants with hyperlipidemia at Baseline)
Percentage of Participants Who Achieved Improvements of NAFLD (only for participants who are diagnosed as NAFLD by Magnetic Resonance Imaging (MRI) at Baseline)
Percentage of Participants Who Achieved Improvements of NAFLD (only for participants who are diagnosed as NAFLD by MRI at Baseline)
Percentage of Participants Who Achieve ≥10% body weight reduction
Percentage of Participants Who Achieve ≥10% body weight reduction
Percentage of Participants Who Achieve ≥15% body weight reduction
Percentage of Participants Who Achieve ≥15% body weight reduction
Change from Baseline in Absolute Body Weight
Change from Baseline in Absolute Body Weight
Change from Baseline in BMI
Change from Baseline in BMI
Change from Baseline in Visceral Adipose Tissue (VAT)
Change from Baseline in VAT will be collected by single slice imaging at the umbilicus level in a supine position using computerized tomography (CT).
Change from Baseline in Subcutaneous Adipose Tissue (SAT)
Change from Baseline in SAT will be collected by single slice imaging at the umbilicus level in a supine position using CT.
Change from Baseline in VAT/SAT Ratio
Change from Baseline in VAT/SAT Ratio
Percentage of Participants Who Achieve VAT <100 square centimeter (cm²) from Baseline (only for participants with VAT≥100 cm2 at Baseline)
Percentage of Participants Who Achieve VAT <100 cm² from Baseline (only for participants with VAT≥100 cm2 at Baseline)
Change from Baseline in Waist Circumference
Change from Baseline in Waist Circumference
Change from Baseline in Hemoglobin A1c (HbA1c)
Change from Baseline in HbA1c
Change from Baseline in Fasting Insulin
Change from Baseline in Fasting Insulin
Change from Baseline in Systolic Blood Pressure
Change from Baseline in Systolic Blood Pressure
Change from Baseline in Diastolic Blood Pressure
Change from Baseline in Diastolic Blood Pressure
Change from Baseline in Short Form 36 Version 2 Health Survey (SF-36v2) Acute Form Physical Functioning Domain Score
Change from Baseline in SF-36v2 Acute Form Physical Functioning Domain Score
Change from Baseline in Change in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score
Change from Baseline in Change in IWQOL-Lite-CT Physical Function score
Change from Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L)
Change from Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L)

Full Information

First Posted
April 1, 2021
Last Updated
August 7, 2023
Sponsor
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT04844918
Brief Title
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
Acronym
SURMOUNT-J
Official Title
Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
May 10, 2021 (Actual)
Primary Completion Date
June 24, 2023 (Actual)
Study Completion Date
June 24, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Metabolism and Nutrition Disorder, Obesity Related Health Problems, Obesity Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
267 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tirzepatide Regimen A
Arm Type
Experimental
Arm Description
Tirzepatide Regimen A administered subcutaneously (SC)
Arm Title
Tirzepatide Regimen B
Arm Type
Experimental
Arm Description
Tirzepatide Regimen B administered subcutaneously (SC)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo administered SC
Intervention Type
Drug
Intervention Name(s)
Tirzepatide
Other Intervention Name(s)
LY3298176
Intervention Description
Administered SC
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Administered SC
Primary Outcome Measure Information:
Title
Percentage of Participants who Achieve ≥5% Body Weight Reduction
Description
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Time Frame
Week 72
Title
Percent Change in Body Weight
Description
Percent Change in Body Weight
Time Frame
Baseline, 72 Weeks
Secondary Outcome Measure Information:
Title
Percentage of Participants Who Had Improvement in Obesity-related Health Problems
Description
Percentage of participants who had improvement in at least 2 obesity-related health problems in participants with a baseline body mass index (BMI) ≥27 and <35 kilogram per square meter (kg/m²) or improvement in at least 1 obesity-related health problems in participants with a baseline BMI ≥35 kg/m²
Time Frame
Week 72
Title
Change from Baseline in Oral Glucose Tolerance (OGTT) 2-hr Glucose (Only for Participant with Impaired Glucose Tolerance [IGT] at Baseline)
Description
Change from Baseline in OGTT 2-hr Glucose (Only for Participants with IGT at Baseline)
Time Frame
Baseline, Week 72
Title
Change from Baseline in Fasting Glucose (Only for Participants with IGT at Baseline)
Description
Change from Baseline in Fasting Glucose (Only for Participants with IGT at Baseline)
Time Frame
Baseline, Week 72
Title
Change from Baseline in Fasting Lipids [Triglycerides (TG)] (Only for Participants with hyperlipidemia at Baseline)
Description
Change from Baseline in Fasting Lipids TG (Only for Participants with hyperlipidemia at Baseline)
Time Frame
Baseline, Week 72
Title
Change from Baseline in Hepatic Fat Fraction (HFF) (only for participants diagnosed as Non-alcoholic Fatty Liver Disease [NAFLD] by Magnetic Resonance Imaging (MRI) at Baseline)
Description
Change from Baseline in HFF (only for participants diagnosed as NAFLD by MRI at Baseline)
Time Frame
Baseline, Week 72
Title
Percentage of Participants Who Achieved Improvements of IGT (Only for Participants with IGT at Baseline)
Description
Percentage of Participants Who Achieved Improvements of IGT (Only for Participants with IGT at Baseline)
Time Frame
Week 72
Title
Percentage of Participants Who Achieved Improvements of Hyperlipidemia (Only for Participants with Hyperlipidemia at Baseline)
Description
Percentage of Participants Who Achieved Improvements of Hyperlipidemia (only for participants with hyperlipidemia at Baseline)
Time Frame
Week 72
Title
Percentage of Participants Who Achieved Improvements of NAFLD (only for participants who are diagnosed as NAFLD by Magnetic Resonance Imaging (MRI) at Baseline)
Description
Percentage of Participants Who Achieved Improvements of NAFLD (only for participants who are diagnosed as NAFLD by MRI at Baseline)
Time Frame
Week 72
Title
Percentage of Participants Who Achieve ≥10% body weight reduction
Description
Percentage of Participants Who Achieve ≥10% body weight reduction
Time Frame
Week 72
Title
Percentage of Participants Who Achieve ≥15% body weight reduction
Description
Percentage of Participants Who Achieve ≥15% body weight reduction
Time Frame
Week 72
Title
Change from Baseline in Absolute Body Weight
Description
Change from Baseline in Absolute Body Weight
Time Frame
Baseline, Week 72
Title
Change from Baseline in BMI
Description
Change from Baseline in BMI
Time Frame
Baseline, Week 72
Title
Change from Baseline in Visceral Adipose Tissue (VAT)
Description
Change from Baseline in VAT will be collected by single slice imaging at the umbilicus level in a supine position using computerized tomography (CT).
Time Frame
Baseline, Week 72
Title
Change from Baseline in Subcutaneous Adipose Tissue (SAT)
Description
Change from Baseline in SAT will be collected by single slice imaging at the umbilicus level in a supine position using CT.
Time Frame
Baseline, Week 72
Title
Change from Baseline in VAT/SAT Ratio
Description
Change from Baseline in VAT/SAT Ratio
Time Frame
Baseline, Week 72
Title
Percentage of Participants Who Achieve VAT <100 square centimeter (cm²) from Baseline (only for participants with VAT≥100 cm2 at Baseline)
Description
Percentage of Participants Who Achieve VAT <100 cm² from Baseline (only for participants with VAT≥100 cm2 at Baseline)
Time Frame
Week 72
Title
Change from Baseline in Waist Circumference
Description
Change from Baseline in Waist Circumference
Time Frame
Baseline, Week 72
Title
Change from Baseline in Hemoglobin A1c (HbA1c)
Description
Change from Baseline in HbA1c
Time Frame
Baseline, Week 72
Title
Change from Baseline in Fasting Insulin
Description
Change from Baseline in Fasting Insulin
Time Frame
Baseline, Week 72
Title
Change from Baseline in Systolic Blood Pressure
Description
Change from Baseline in Systolic Blood Pressure
Time Frame
Baseline, Week 72
Title
Change from Baseline in Diastolic Blood Pressure
Description
Change from Baseline in Diastolic Blood Pressure
Time Frame
Baseline, Week 72
Title
Change from Baseline in Short Form 36 Version 2 Health Survey (SF-36v2) Acute Form Physical Functioning Domain Score
Description
Change from Baseline in SF-36v2 Acute Form Physical Functioning Domain Score
Time Frame
Baseline, Week 72
Title
Change from Baseline in Change in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score
Description
Change from Baseline in Change in IWQOL-Lite-CT Physical Function score
Time Frame
Baseline, Week 72
Title
Change from Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L)
Description
Change from Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L)
Time Frame
Baseline, Week 72

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have a BMI of greater than or equal to ≥27 kg/m² and <less than 35 kg/m² with at least 2 obesity-related health problems or ≥35 kg/m² with at least 1 obesity-related health problems. Health problems are IGT, hyperlipidemia, or NAFLD. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria: Have diabetes. Acute or chronic liver disease other than NAFLD. Have a self-reported change in body weight >5 kg within 3 months prior to screening. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months. Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2, calculated by Japanese Society of Nephrology coefficient-modified Chronic Kidney Disease-Epidemiology equation during screening. Have a known clinically significant gastric emptying abnormality. Have had a history of chronic or acute pancreatitis. Have thyroid-stimulating hormone outside of the range of 0.4 to 6.0 micro units per milliliter (μIU/mL) at screening. Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity. Have a history of significant active or unstable major depressive disorder or other severe psychiatric disorder within the last 2 years. Have a cardiovascular condition within 3 months prior to randomization Have a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome type 2.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Call 1-877-CTLilly (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST)
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
Kohnodai Hospital, National Center for Global Health and Medicine
City
Ichikawa
State/Province
Chiba
ZIP/Postal Code
272-8516
Country
Japan
Facility Name
Saiseikai Matsuyama Hospital
City
Matsuyama
State/Province
Ehime
ZIP/Postal Code
791-8026
Country
Japan
Facility Name
Takai Internal Medicine Clinic
City
Kamakura-shi
State/Province
Kanagawa
ZIP/Postal Code
247-0056
Country
Japan
Facility Name
Motomachi Takatsuka Naika Clinic
City
Yokohama-city
State/Province
Kanagawa
ZIP/Postal Code
231-0023
Country
Japan
Facility Name
Saiseikai Yokohamashi Tobu Hospital
City
Yokohama
State/Province
Kanagawa
ZIP/Postal Code
2308765
Country
Japan
Facility Name
Medical Corporation Heishinkai OCROM Clinic
City
Suita-shi
State/Province
Osaka
ZIP/Postal Code
565-0853
Country
Japan
Facility Name
Osaka Saiseikai Suita hospital
City
Suita
State/Province
Osaka
ZIP/Postal Code
564-0013
Country
Japan
Facility Name
Takatsuki Red Cross Hospital
City
Takatsuki
State/Province
Osaka
ZIP/Postal Code
569-1045
Country
Japan
Facility Name
The Institute for Adult Disease, Asahi Life Foundation
City
Chuo-ku
State/Province
Tokyo
ZIP/Postal Code
103-0002
Country
Japan
Facility Name
Tokyo-Eki Center-building Clinic
City
Chuo-ku
State/Province
Tokyo
ZIP/Postal Code
103-0027
Country
Japan
Facility Name
Medical Corporation Chiseikai Tokyo Center Clinic
City
Chuo-ku
State/Province
Tokyo
ZIP/Postal Code
103-0028
Country
Japan
Facility Name
Fukuwa Clinic
City
Chuo-ku
State/Province
Tokyo
ZIP/Postal Code
104-0031
Country
Japan
Facility Name
Saiseikai Central Hospital
City
Minato-Ku
State/Province
Tokyo
ZIP/Postal Code
108-0073
Country
Japan
Facility Name
Shimokitazawa Tomo Clinic
City
Setagaya-ku
State/Province
Tokyo
ZIP/Postal Code
155-0031
Country
Japan
Facility Name
Miho Clinic
City
Shinagawa-ku
State/Province
Tokyo
ZIP/Postal Code
141 0032
Country
Japan
Facility Name
Medical Corporation Heishinkai ToCROM Clinic
City
Shinjuku-ku
State/Province
Tokyo
ZIP/Postal Code
160 0008
Country
Japan
Facility Name
Yamagata Tokushukai Hospital
City
Yamagata-shi
State/Province
Yamagata
ZIP/Postal Code
990-0834
Country
Japan
Facility Name
AMC Nishiumeda Clinic
City
Osaka
ZIP/Postal Code
530-0001
Country
Japan

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD Sharing Time Frame
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD Sharing Access Criteria
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD Sharing URL
https://vivli.org/

Learn more about this trial

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

We'll reach out to this number within 24 hrs